Immunogenicity and Reactogenicity of Ad26.COV2.S in Korean Adults: A Prospective Cohort Study

被引:1
|
作者
Hyun, Hakjun [1 ]
Choi, Min Joo [4 ,7 ]
Heo, Jung Yeon [5 ]
Seo, Yu Bin [6 ]
Nham, Eliel [1 ]
Yoon, Jin Gu [1 ]
Seong, Hye [1 ]
Noh, Ji Yun [1 ,2 ,3 ]
Cheong, Hee Jin [1 ]
Kim, Woo Joo [1 ,2 ,3 ]
Choi, Ju-Yeon
Lee, Young Jae
Lee, Hye Won
Kim, Sung Soon
Kim, Byoungguk
Song, Joon Young [1 ,2 ,3 ]
机构
[1] Korea Univ, Dept Internal Med, Div Infect Dis, Coll Med, Seoul, South Korea
[2] Korea Univ, Asia Pacific Influenza Inst, Coll Med, Seoul, South Korea
[3] Vaccine Innovat Ctr KU Med VIC K, Seoul, South Korea
[4] Catholic Kwandong Univ, Dept Internal Med, Int St Marys Hosp, Coll Med, Incheon, South Korea
[5] Ajou Univ, Dept Infect Dis, Sch Med, Suwon, South Korea
[6] Hallym Univ, Kangnam Sacred Heart Hosp, Dept Internal Med, Div Infect Dis,Coll Med, Seoul, South Korea
[7] Natl Inst Infect Dis, Ctr Vaccine Res, Div Vaccine Clin Res, Cheongju, South Korea
关键词
SARS-CoV-2; COVID-19; Vaccines; Adenovirus Vector; Humoral Immunity; Cellular Immunity; Adverse Events;
D O I
10.3346/jkms.2022.37.e210
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: As the coronavirus disease 2019 (COVID-19) pandemic continues, there are concerns regarding waning immunity and the emergence of viral variants. The immunogenicity of Ad26.COV2.S against wild-type (WT) and variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) needs to be evaluated. Method: This prospective cohort study was conducted between June 2021 and January 2022 at two university hospitals in South Korea. Healthy adults who were scheduled to be vaccinated with Ad26.COV2.S were enrolled in this study. The main outcomes included anti-spike (S) IgG antibody and neutralizing antibody responses, S-specific T-cell responses (interferon-. enzyme-linked immunospot assay), solicited adverse events (AEs), and serious AEs. Results: Fifty participants aged >= 19 years were included in the study. Geometric mean titers (GMTs) of anti-S IgG were 0.4 U/mL at baseline, 5.2 +/- 3.0 U/mL at 3-4 weeks, 55.7 +/- 2.4 U/mL at 5-8 weeks, and 81.3 +/- 2.5 U/mL at 10-12 weeks after vaccination. GMTs of 50% neutralizing dilution (ND50) against WT SARS- CoV-2 were 164.6 +/- 4.6 at 3-4 weeks, 313.9 +/- 3.6 at 5-8 weeks, and 124.4 +/- 2.6 at 10-12 weeks after vaccination. As for the S-specific T-cell responses, the median number of spot-forming units/106 peripheral blood mononuclear cell was 25.0 (5.0-29.2) at baseline, 60.0 (23.3-178.3) at 5-8 weeks, and 35.0 (13.3-71.7) at 10-12 weeks after vaccination. Compared to WT SARS-CoV-2, ND50 against Delta and Omicron variants was attenuated by 3.6-fold and 8.2-fold, respectively. The most frequent AE was injection site pain (82%), followed by myalgia (80%), fatigue (70%), and fever (50%). Most AEs were grade 1-2, and resolved within two days. Conclusion: Single-dose Ad26.COV2.S was safe and immunogenic. NAb titer and S-specific T-cell immunity peak at 5-8 weeks and rather decrease at 10-12 weeks after vaccination. Cross-reactive neutralizing activity against the Omicron variant was negligible.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Safety and immunogenicity of Ad26.COV2.S in adolescents: Phase 2 randomized clinical trial
    Tica, Jelena
    Rezelj, Veronica V.
    Baron, Benoit
    van Paassen, Vitalija
    Zaidman, Javier
    Fairlie, Lee
    Scheper, Gert
    Le Gars, Mathieu
    Struyf, Frank
    Douoguih, Macaya
    Ruiz-Guinazu, Javier
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2025, 21 (01)
  • [2] Safety, reactogenicity, and immunogenicity of Ad26.COV2.S as homologous or heterologous COVID-19 booster vaccination: Results of a randomized, double-blind, phase 2 trial
    Le Gars, Mathieu
    Sadoff, Jerald
    Cardenas, Vicky
    Heerwegh, Dirk
    Tesfaye, Fisseha
    Van Roey, Griet
    Spicer, Colleen
    Matias, Samantha Santoro
    Crayne, Olivia
    Kamphuis, Tobias
    Struyf, Frank
    Schuitemaker, Hanneke
    Douoguih, Macaya
    VACCINE, 2024, 42 (19) : 3938 - 3952
  • [3] Immunogenicity and efficacy of Ad26.COV2.S: An adenoviral vector-based COVID-19 vaccine
    Le Gars, Mathieu
    Hendriks, Jenny
    Sadoff, Jerry
    Ryser, Martin
    Struyf, Frank
    Douoguih, Macaya
    Schuitemaker, Hanneke
    IMMUNOLOGICAL REVIEWS, 2022, 310 (01) : 47 - 60
  • [4] Safety and immunogenicity of Ad26.COV2.S in adults: A randomised, double-blind, placebo-controlled Phase 2a dose-finding study
    Cardenas, Vicky
    Le Gars, Mathieu
    Truyers, Carla
    Ruiz-Guinazu, Javier
    Struyf, Frank
    Colfer, Alicia
    Bonten, Marc
    Borobia, Alberto
    Reisinger, Emil C.
    Kamerling, Ingrid M. C.
    Douoguih, Macaya
    Sadoff, Jerald
    VACCINE, 2024, 42 (16) : 3536 - 3546
  • [5] Multisystem Inflammatory Syndrome after Ad26.COV2.S vaccination
    Bova, Carlo
    Vigna, Ernesto
    Gentile, Massimo
    IDCASES, 2022, 27
  • [6] Impact of Preexisting Anti-Adenovirus 26 Humoral Immunity on Immunogenicity of the Ad26.COV2.S Coronavirus Disease 2019 Vaccine
    Le Gars, Mathieu
    Sadoff, Jerald
    Struyf, Frank
    Heerwegh, Dirk
    Truyers, Carla
    Hendriks, Jenny
    Gray, Glenda
    Grinsztejn, Beatriz
    Goepfert, Paul A.
    Schuitemaker, Hanneke
    Douoguih, Macaya
    JOURNAL OF INFECTIOUS DISEASES, 2022, 226 (06) : 979 - 982
  • [7] Safety, reactogenicity, and immunogenicity of Ad26.COV2.S: Results of a phase 1, randomized, double-blind, placebo-controlled COVID-19 vaccine trial in Japan
    Tsuchiya, Yumi
    Tamura, Hiroshi
    Fujii, Koji
    Numaguchi, Hirotaka
    Toyoizumi, Kiichiro
    Liu, Tina
    Le Gars, Mathieu
    Cardenas, Vicky
    Eto, Takashi
    VACCINE, 2023, 41 (09) : 1602 - 1610
  • [8] Guillain-Barre Syndrome After Ad26.COV2.S Vaccination
    Thant, Hein Linn
    Morgan, Richard
    Paese, Mario M.
    Persaud, Trevor
    Diaz, Jose
    Hurtado, Lina
    AMERICAN JOURNAL OF CASE REPORTS, 2022, 23
  • [9] Rhabdomyolysis Following Ad26.COV2.S COVID-19 Vaccination
    Gelbenegger, Georg
    Cacioppo, Filippo
    Firbas, Christa
    Jilma, Bernd
    VACCINES, 2021, 9 (09)
  • [10] Ad26.COV2.S COVID-19 Vaccine Safety And Immunogenicity in Adolescents 16-17 Years of Age
    Ruiz-Guinazu, Javier
    Le Gars, Mathieu
    Cardenas, Vicky
    Vaissiere, Nathalie
    Sadoff, Jerald
    Truyers, Carla
    Hendriks, Jenny
    Scheper, Gert
    de Groot, A. Marit
    Struyf, Frank
    Schuitemaker, Hanneke
    Douoguih, Macaya
    JOURNAL OF THE PEDIATRIC INFECTIOUS DISEASES SOCIETY, 2024, 13 (11) : 599 - 601